BioAtla/$BCAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioAtla
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Ticker
$BCAB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
61
ISIN
US09077B1044
Website
BioAtla Metrics
BasicAdvanced
$22M
-
-$1.21
0.91
-
Price and volume
Market cap
$22M
Beta
0.91
52-week high
$2.19
52-week low
$0.24
Average daily volume
524K
Financial strength
Current ratio
2.345
Quick ratio
2.022
Total debt to equity
101.28
Profitability
EBITDA (TTM)
-66.232
Gross margin (TTM)
-414.53%
Net profit margin (TTM)
-562.51%
Operating margin (TTM)
-610.00%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
-65.79%
Return on equity (TTM)
-246.21%
Valuation
Price to revenue (TTM)
1.784
Price to book
41
Price to tangible book (TTM)
41
Price to free cash flow (TTM)
-0.342
Free cash flow yield (TTM)
-292.43%
Free cash flow per share (TTM)
-112.29%
Growth
Earnings per share change (TTM)
-51.36%
3-year revenue growth (CAGR)
253.03%
3-year earnings per share growth (CAGR)
-24.79%
What the Analysts think about BioAtla
Analyst ratings (Buy, Hold, Sell) for BioAtla stock.
BioAtla Financial Performance
Revenues and expenses
BioAtla Earnings Performance
Company profitability
BioAtla News
AllArticlesVideos
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
GlobeNewsWire·2 months ago
BioAtla to Participate in the Citizens Life Sciences Conference
GlobeNewsWire·2 months ago
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioAtla stock?
BioAtla (BCAB) has a market cap of $22M as of July 01, 2025.
What is the P/E ratio for BioAtla stock?
The price to earnings (P/E) ratio for BioAtla (BCAB) stock is 0 as of July 01, 2025.
Does BioAtla stock pay dividends?
No, BioAtla (BCAB) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next BioAtla dividend payment date?
BioAtla (BCAB) stock does not pay dividends to its shareholders.
What is the beta indicator for BioAtla?
BioAtla (BCAB) has a beta rating of 0.91. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.